agm notes, page-7

Hey Shareinspector, I loved the bullishness they had for HA-Irinotecan, we are well advanced over competition and this will be a new branded product claiming superiority over existing Irinotecan and its generics. People should check out the AGM presentation and I especially liked slide 26 "Potential conversion to HA-Irinotecan" from the recent US Survey on HA-Irinotecan entitled:

?Role of irinotecan in chemotherapy of metastatic colorectal cancer (mCRC)?

As far as the distribution of earnings to shareholders I hope they keep it and progress the company agrresively, both on the HyACT front and Oral Fonda. I'm sure once we get FDA approval for Fonda then shareholders will be taken care of by way of capital appreciation, dividends should maybe start after we have entered Europe for Fonda and we are sure of HA-Irinotecan success and where we are at with Oral Fonda, but that's just my view as I can wait on earning a divy and don't need the income as such, I'm more for capital growth and opportunity, but everyones situation is different - eg age.

I know when I'm doing the HC stock tipping comp what my first pick will be!!